Researchers performed untargeted metabolomics on plasma samples from the 60 participants to identify molecular differences between pancreatic cancer cases and controls. Differential metabolites were identified using orthogonal partial least-squares discriminant analysis, with thresholds of a variable importance in projection score above 1, a fold change greater than 2 or below 0.5, and an adjusted P value below 0.05. Thirty-four plasma metabolites significantly distinguished the groups, and the altered metabolites were primarily enriched in the arginine biosynthesis pathway.

The team next used multivariate ROC analysis with internal validation to prioritize potential diagnostic biomarkers. The five metabolites with the highest variable importance in projection scores were 4-oxoproline, 1,4-dimethylpiperazine, pyridoxamine, urocanic acid and L-cysteine-S-sulfate. Their analysis placed particular emphasis on 1,4-dimethylpiperazine because its diagnostic performance was similar to that of CA19-9 in this cohort and no significant relationship was found with the assessed liver-function parameters or C-reactive protein, or CRP.

Those associations were evaluated through Spearman correlation and multiple linear regression analyses. CA19-9 showed a positive correlation with gamma-glutamyl transferase, or GGT, with a correlation coefficient of 0.364. By contrast, 1,4-dimethylpiperazine was not significantly associated with liver-function parameters or CRP. The reported null association applies only to the measures and participants included in this study and does not establish that the metabolite is free from liver or inflammatory influences in other populations.

Combining 1,4-dimethylpiperazine with CA19-9 increased the AUC to 0.982. This combined value was significantly higher than the AUC for 1,4-dimethylpiperazine alone, which was 0.893 (P = 0.035). It did not, however, significantly outperform CA19-9 alone, for which the AUC was 0.904; the comparison between the combination and CA19-9 yielded P = 0.076. Thus, the study provides statistical evidence of added performance relative to the metabolite by itself, but not of a significant advantage over CA19-9 by itself.

OPLS-DA also separated the pancreatic cancer group into two subclusters that differed in alkaline phosphatase levels and smoking history. This observation indicates heterogeneity within the cancer cases included in the exploratory cohort. It also matters for interpreting the diagnostic results: the reported AUC values came from a selected sample of 30 pancreatic cancer patients and 30 healthy controls, with internal validation rather than assessment in a larger, independently validated cohort.

Pancreatic cancer is an aggressive malignancy, and the study reports a five-year survival rate below 10%. CA19-9 is the most commonly used serum biomarker for pancreatic cancer diagnosis, but the investigators noted that cholestasis and inflammation can influence it. The study therefore examined whether plasma metabolites could identify pancreatic cancer without the significant associations with liver function or inflammation detected for 1,4-dimethylpiperazine in this cohort. The findings do not establish improved early detection, replacement of CA19-9, or better patient outcomes.

The authors characterized 1,4-dimethylpiperazine as a promising complementary biomarker and called for validation in larger, disease-controlled cohorts. Within the 60-person study, its AUC was similar to that of CA19-9, its combination with CA19-9 significantly improved performance over 1,4-dimethylpiperazine alone, and no significant association was detected with the liver-function and inflammatory measures evaluated. These exploratory results support further evaluation, while the small sample and internally validated analysis limit how broadly the findings can be applied.

Subject of Research: Exploratory evaluation of 1,4-dimethylpiperazine as a plasma diagnostic biomarker for pancreatic cancer.

Article Title: Plasma metabolite 1,4-dimethylpiperazine: a valuable diagnostic biomarker with no significant association with liver function or inflammation

Article References: Wang, X., Sun, H., Yang, T., Liu, W., Yang, H., Zhang, J., Yu, D., Wang, M., Xu, J., Shan, Z., Qiu, X., Wang, C., & Li, M. (2026). Plasma metabolite 1,4-dimethylpiperazine: a valuable diagnostic biomarker with no significant association with liver function or inflammation. BMC Cancer. https://doi.org/10.1186/s12885-026-17015-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17015-w

Keywords: pancreatic cancer, 1,4-dimethylpiperazine, plasma metabolomics, CA19-9, diagnostic biomarkers, liver function, inflammation, ROC analysis, Plasma, metabolite, dimethylpiperazine, valuable

The study included 801 patients who underwent NAT2 genotyping at Henan Provincial Chest Hospital between January 2021 and May 2024. The full cohort was used to characterize the distribution of slow, intermediate and fast acetylator status. The primary analysis was restricted to 554 patients who had normal liver function at admission and a recorded isoniazid dose, while a secondary cohort comprised 690 patients with normal baseline liver function. The principal comparison was slow acetylator status with non-slow status, including intermediate and fast acetylators combined.

Across the 801 participants, 369 (46.1%) were intermediate acetylators, 278 (34.7%) were fast acetylators and 154 (19.2%) were slow acetylators. New liver function abnormalities occurred in 28.7% (29/101) of slow acetylators and 25.2% (114/453) of non-slow acetylators in the primary cohort, yielding a crude odds ratio of 1.20 (95% confidence interval [CI], 0.73–1.92; P = 0.462). Adjustment for age, sex and recorded isoniazid dose produced a similar estimate: adjusted OR, 1.18 (95% CI, 0.72–1.89; P = 0.507). An additional analysis adjusting for pulmonary tuberculosis and isoniazid susceptibility gave an OR of 1.18 (95% CI, 0.72–1.90; P = 0.505). Secondary and sensitivity analyses were reported as consistent with the primary result.

The findings remain limited by the study’s retrospective, single-center design and the statistical uncertainty surrounding the estimated association. At 80% power, the approximate minimum detectable odds ratio for a risk-increasing association was 1.94, meaning the available analysis was not sufficiently precise to rule out smaller effects. The outcome was not causally adjudicated as antituberculosis-drug-induced liver injury, and systematic pharmacokinetic and longitudinal treatment data were unavailable. The abstract therefore concludes that the results do not establish the clinical utility of NAT2-guided dosing. Prospective multicenter validation is needed, and the findings should not be interpreted as evidence that genotype-guided dosing lacks clinical value.

Subject of Research: NAT2 genotype-inferred acetylator status and new liver function abnormalities in patients with tuberculosis

Article Title: The distribution of N-acetyltransferase 2 genotypes in a cohort of tuberculosis patients in a single center in Henan Province of China

Article References: Li, J., Chen, L., Shi, H., Zhao, C., Xu, P., Mo, Y., Liu, X., Zhao, Y., & Liang, R. (2026). The distribution of N-acetyltransferase 2 genotypes in a cohort of tuberculosis patients in a single center in Henan Province of China. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14424-x

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14424-x

Keywords: NAT2, tuberculosis, acetylator status, liver function, isoniazid, retrospective cohort, Henan Province, pharmacogenetics, distribution, N-acetyltransferase, genotypes, cohort

The review, led by Professor Hong You and Dr. Bingqiong Wang of the Liver Research Center at Beijing Friendship Hospital, Capital Medical University, examines evidence on recompensation across the major causes of cirrhosis. Published in the journal Portal Hypertension & Cirrhosis, the work synthesizes data on how often recompensation occurs, what criteria should define it, which factors predict it, what is known about its biological basis, and how patients who recover should be monitored over the long term. The authors’ central proposal is that recompensation should be recognized as a distinct, treatment-related disease state rather than treated as a vague synonym for improvement.

The shift in thinking rests on a growing body of evidence that effective treatment of the underlying cause of cirrhosis can allow some patients to regain liver function and resolve the complications that defined their decompensation. In viral hepatitis, potent antiviral therapy can suppress replication and reduce inflammation; in alcohol-related liver disease, sustained abstinence can remove the ongoing injurious stimulus; in autoimmune and cholestatic conditions, targeted immunosuppression or other therapies can alter disease activity. When the driver of scarring is controlled, the liver’s residual regenerative capacity can, in a subset of patients, translate into measurable clinical recovery.

Yet recovery, the authors emphasize, is neither automatic nor uniform. Under the Baveno VII consensus, an international framework widely used in hepatology, recompensation is defined by three requirements: control of the underlying cause of cirrhosis, sustained resolution of decompensation events without the need for supportive treatment such as diuretics or non-selective beta-blockers, and stable improvement in liver function. Meeting these criteria is demanding, and the new review makes clear that many patients who improve do not fully satisfy them, while others who do may later lose that status.

How often does recompensation actually occur? A meta-analysis of 27 studies encompassing 9,063 patients found a pooled prevalence of approximately 35 percent, though the figure varied dramatically by etiology. Around 50 percent of patients with hepatitis B virus-related cirrhosis achieved recompensation, compared with only about 15 percent of those with primary biliary cholangitis. In one hepatitis B study, 56.2 percent of 283 treatment-naive patients receiving the antiviral drug entecavir met Baveno VII criteria after 120 weeks of therapy. Among patients with alcohol-related cirrhosis, a multicenter study reported that 31.1 percent achieved recompensation. These numbers suggest that recompensation is far from rare, but also far from universal.

The likelihood of recovery depends on more than simply eliminating the cause. Better baseline liver function, fewer previous decompensation events, and a lower burden of portal hypertension, the elevated pressure in the venous system that drains the gut through the liver, were generally associated with a greater chance of recompensation. The meta-analysis illustrated this gradient starkly: cohorts with a mean Model for End-Stage Liver Disease score below 15 had a pooled recompensation rate of 48 percent, whereas cohorts with scores of 15 or higher achieved only 19 percent. In other words, the reserve remaining in the liver at the moment treatment begins shapes how much recovery is possible.

Intriguingly, clinical improvement appears to be mirrored by measurable biological change. In a small group of 19 patients with alcohol-related cirrhosis who had paired hemodynamic measurements, the median hepatic venous pressure gradient, a direct readout of portal pressure, fell from 19 to 9 mmHg after sustained recovery. That decline represents a substantial hemodynamic improvement and suggests that fibrosis regression and reductions in vascular resistance within the scarred liver can accompany the resolution of clinical complications. However, the same body of data carries a cautionary note: 59 percent of 29 evaluated patients retained clinically significant portal hypertension despite their overall improvement, meaning that the vascular complications of cirrhosis can persist even when the surface picture looks favorable.

Perhaps the most consequential argument in the review is that recompensation can be unstable. In a hepatitis B cohort, 86.8 percent of patients who achieved recompensation by Week 120 maintained it during extended follow-up, but 13.2 percent developed hepatocellular carcinoma, experienced further decompensation, or died. Another study identified unstable recompensation in 24.3 percent of patients. The prognostic separation between recovery states is striking: five-year rates of hepatocellular carcinoma or all-cause mortality were 10.1 percent for stable recompensation, 14.7 percent for unstable recompensation, and 27.3 percent for persistent decompensation. Recovery clearly improves outcomes compared with continued decompensation, but it does not restore the risk profile of a never-decompensated liver.

Recompensation reflects meaningful improvement after effective treatment, but it should not automatically be interpreted as complete reversal of cirrhosis, Professor You cautions. Recognizing it as a distinct treatment-related state, she argues, may help clinicians describe recovery more consistently and identify the patients who remain at risk even after their complications resolve. Dr. Wang reinforces the point from the patient-care perspective: people who improve after cirrhosis treatment may still carry residual risks from portal hypertension, limited hepatic reserve, and liver cancer, so continued surveillance remains important even when clinical signs of decompensation have disappeared. The message for survivors of decompensation is one of cautious optimism rather than discharge from care.

To organize these observations, the authors propose a four-state framework describing where a patient with cirrhosis may sit after the underlying cause has been brought under control: compensated cirrhosis, stable recompensation, unstable recompensation, or persistent decompensation. Such a taxonomy could standardize how clinical trials enroll and stratify patients, how guidelines frame follow-up intervals, and how physicians communicate prognosis. The authors are careful to note that the framework requires prospective validation, particularly in causes of cirrhosis other than hepatitis B, where the evidence base is strongest. Future research, they write, should establish objective markers that distinguish stable from unstable recovery, validate expanded criteria, clarify the mechanisms of fibrosis regression and portal-pressure reduction, and determine whether different recovery trajectories demand different monitoring strategies. If validated, the concept of recompensation as a formal disease state could reshape both research design and everyday hepatology practice for millions of patients living with treated cirrhosis.

Subject of Research: Recompensation as a treatment-related disease state in cirrhosis after control of the underlying cause

Article Title: Recompensation may represent a new treatment-related state in cirrhosis

Article References: Recompensation may represent a new treatment-related state in cirrhosis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cirrhosis, recompensation, liver disease, portal hypertension, decompensation, hepatitis B, hepatocellular carcinoma, fibrosis regression, Baveno VII, liver function, alcohol-related cirrhosis, disease state framework

The research team, led by Lu Zhao and Li-ping Xie, who contributed equally as co-first authors, with Fang Liu and Guo-ying Huang as corresponding authors, retrospectively analyzed the clinical records of children diagnosed with Kawasaki disease complicated by gallbladder abnormalities between 2016 and 2022. From that six-year window, fifteen children met the criteria for inclusion. Eleven were male and four were female, a male predominance that mirrors the sex ratio seen in Kawasaki disease more broadly. The average age at onset was 32 months, with a standard deviation of 20 months, placing these patients squarely in the toddler and preschool age range where Kawasaki disease is most common. The average time from illness onset to diagnosis was 6.4 days, plus or minus 1.8 days, a delay that the authors suggest reflects how easily the gallbladder findings can distract clinicians from the underlying diagnosis.

The clinical presentations in this series were strikingly abdominal. Nine of the fifteen children arrived with gastrointestinal complaints: four with abdominal pain, four with vomiting, and two with diarrhea. Five children had incomplete Kawasaki disease, the form of the illness that fails to satisfy the classic diagnostic criteria of prolonged fever plus four of the five principal features, including rash, conjunctival injection, oral mucosal changes, extremity changes, and cervical lymphadenopathy. Those five children were initially misdiagnosed, a fact that underscores a persistent diagnostic trap. When a febrile toddler vomits and clutches the right side of the belly, the differential diagnosis typically tilts toward appendicitis, cholecystitis, or a viral gastroenteritis, and the possibility of a systemic vasculitis inflaming the gallbladder wall can be overlooked entirely.

Laboratory testing in these fifteen patients revealed a pattern that, in retrospect, pointed toward Kawasaki disease. Inflammatory markers were elevated, and liver function tests were abnormal, with increases in total bilirubin that were predominantly of the direct, or conjugated, type. Alanine aminotransferase, an enzyme released when liver cells are stressed or damaged, was raised, as was γ-glutamyl transferase, an enzyme associated with the biliary system. This combination of conjugated hyperbilirubinemia and elevated hepatobiliary enzymes in a febrile child is a recognized accompaniment of Kawasaki disease, and the authors note that gallbladder involvement in the condition is associated with more intense inflammation. In other words, the sick liver and the swollen gallbladder were not a separate surgical problem but an extension of the same vasculitic process.

Imaging confirmed the gallbladder involvement in every patient, though the specific findings varied. Fourteen of the fifteen children showed gallbladder enlargement on ultrasound, while one child showed thickening of the gallbladder wall instead. Eight children also had hepatomegaly, an enlarged liver, on imaging. Acalculous cholecystitis, inflammation of the gallbladder without gallstones, is the classic gallbladder manifestation of Kawasaki disease, and the ultrasound findings in this series fit that picture. The absence of stones is diagnostically important, because it argues against routine biliary colic and shifts attention toward systemic inflammation as the driving force behind the gallbladder’s distress.

Treatment followed the standard escalation pathway for Kawasaki disease. All fifteen patients received initial therapy with intravenous immunoglobulin at a dose of 2 grams per kilogram of body weight, the internationally accepted first-line treatment that dramatically reduces the risk of coronary artery aneurysms when given promptly. Six patients also received glucocorticoids concurrently with that first dose. The response data were sobering: nine of the fifteen patients, a majority, did not respond to the initial IVIG treatment. This rate of IVIG resistance aligns with the study’s central observation that children with gallbladder abnormalities tend to mount more severe inflammatory responses and are harder to treat than typical Kawasaki disease cases. Resistance to IVIG is itself a recognized risk factor for worse coronary outcomes, which makes early recognition of these patients all the more consequential.

For the children who failed initial therapy, the clinicians escalated aggressively. Nine patients received a second dose of intravenous immunoglobulin. Six patients received glucocorticoids at 1 to 2 milligrams per kilogram, and two patients required higher doses of 5 to 10 milligrams per kilogram. Beyond immunosuppression, supportive hepatobiliary care played a prominent role: eleven patients were treated with hepatoprotective and choleretic drugs, medications intended to shield liver cells and promote bile flow. One child underwent gallbladder drainage, the only invasive procedural intervention in the series. Notably, no child in the cohort required gallbladder surgery, a point the authors emphasize as evidence that aggressive anti-inflammatory therapy can render operative management unnecessary in most cases.

The outcomes were uniformly favorable. Clinical symptoms improved in all fifteen children, and blood counts and biochemistry panels returned to normal. Eleven children were followed with repeat abdominal ultrasound, and the imaging told a reassuring story of resolution. In five cases the gallbladder had normalized completely by two months of follow-up, with the actual time to normalization ranging from one to seven months. In the remaining six cases the gallbladder had already decreased in size by the one-month mark. This trajectory of gradual, medication-driven resolution contrasts sharply with the natural history of surgical gallbladder disease and reinforces the argument that these children need immunomodulation, not an operating room.

The broader significance of the study lies in its diagnostic lesson. Kawasaki disease affects children predominantly, and its incomplete form is notoriously difficult to catch, yet the coronary consequences of missing it are severe. Gallbladder abnormalities, particularly an enlarged, stone-free gallbladder in a febrile young child with abdominal pain, vomiting, or diarrhea, should prompt clinicians to consider Kawasaki disease in the differential and to look for the supporting evidence: conjunctival redness, mucosal changes, rash, and the characteristic laboratory signature of elevated inflammatory markers and hepatobiliary enzymes. The Shanghai series suggests that when gastrointestinal symptoms dominate the presentation, the gallbladder may be the first organ to announce the vasculitis, and recognizing that signal can shorten the path to IVIG treatment within the critical first ten days of illness.

As a single-center retrospective case series of fifteen patients, the study has inherent limitations, including its modest sample size and its reliance on records from one large Chinese children’s hospital. The authors are careful to frame their conclusions accordingly. Even so, the clinical course they document, from misdiagnosis to aggressive anti-inflammatory therapy to full recovery without surgery, offers a concrete template for pediatricians encountering the same puzzle. For a disease in which timing is everything and the stakes are the coronary arteries of young children, an unexpected gallbladder finding may be far more than a gastrointestinal curiosity; it may be the clue that saves a heart.

Subject of Research: Gallbladder abnormalities in children with Kawasaki disease

Article Title: Gallbladder abnormalities in Kawasaki disease: a single-center case series study

Article References: Zhao, L., Xie, L.-P., Zhao, Q.-M., He, L., Chu, C., Liang, X.-C., Liu, F., & Huang, G.-Y. (2026). Gallbladder abnormalities in Kawasaki disease: a single-center case series study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07719-0

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07719-0

Keywords: Kawasaki disease, gallbladder abnormalities, acalculous cholecystitis, IVIG resistance, pediatric vasculitis, incomplete Kawasaki disease, gastrointestinal symptoms, liver function, abdominal ultrasound, glucocorticoids, coronary artery lesions, BMC Pediatrics

The research, led by Allan Wandera of the Department of Biochemistry at Lira University and colleagues from institutions including Soroti University, was published in BMC Endocrine Disorders. It enrolled 54 HIV-positive adults with type 2 diabetes, all of whom had been receiving both antiretroviral therapy and glucose-lowering medication for at least six months at the hospital’s Chronic Care Clinic. The study was funded by the Lira University Research and Innovations Fund, financed by the Government of Uganda for the 2023/2024 cycle, and approved by the Lira University Research Ethics Committee under approval number LUREC-2025-400, with administrative clearance from the hospital itself. Every participant provided written informed consent, and the work was conducted in line with the Declaration of Helsinki.

The clinical backdrop is important for understanding why the study exists. Dolutegravir-based regimens are now recommended widely because they are potent, durable, and have a high genetic barrier to resistance. Yet at Lira Regional Referral Hospital, diabetic patients are frequently switched away from dolutegravir onto alternative combinations, most commonly tenofovir disoproxil fumarate, lamivudine, and efavirenz, known as TDF/3TC/EFV, or onto protease inhibitor-based or abacavir-based therapies. The metabolic consequences of these non-dolutegravir regimens in patients who also have diabetes had not been systematically documented, leaving clinicians without evidence to guide treatment choices for a growing and vulnerable subgroup.

To fill that gap, the researchers combined a review of medical records with fresh laboratory investigations. Blood samples were drawn to measure glycated hemoglobin, or HbA1c, the standard long-term marker of blood glucose control, along with liver function tests, kidney function tests, lipid profiles, and CD4 cell counts. Viral load data were retrieved from patient records. Participants were then sorted into six groups according to the specific combination of antiretroviral therapy and diabetes medication they were receiving, and the investigators applied descriptive statistics and one-way analysis of variance to compare outcomes across the groups.

The virological picture was reassuring. Every participant had a documented suppressed viral load, and CD4 counts were above 350 cells per cubic millimeter in all cases, with a mean of 518.5 plus or minus 56.8 cells per cubic millimeter. In other words, whatever regimen the patients were taking, their HIV infection was well controlled. The cohort itself skewed female and middle-aged to older: 70.4 percent of participants were women, and the average age was 54.8 plus or minus 9.5 years. These demographics reflect the broader epidemiological shift in sub-Saharan Africa, where an aging population of people living with HIV is increasingly confronting non-communicable diseases.

Glycemic control, however, told a more complicated story. HbA1c values varied significantly across the six treatment groups, and the statistical analysis confirmed that this variation was unlikely to be due to chance, with an F statistic of 3.794 and a p value of 0.006. The lowest average HbA1c, 7.81 percent, was recorded in the largest group, 23 patients taking TDF/3TC/EFV combined with metformin alone. The next lowest was a small group of four patients on abacavir, lamivudine, and efavirenz without insulin or protease inhibitors, at 8.50 percent, followed by five patients on protease inhibitor-based therapy without insulin at 8.94 percent. Patients on TDF/3TC/EFV with both metformin and glibenclamide averaged 9.43 percent, those on TDF/3TC/EFV with insulin averaged 9.47 percent, and the highest figure, 11.08 percent, appeared in a group of four patients on other highly active antiretroviral combinations with insulin. Post-hoc testing pinpointed one statistically significant pairwise difference: the metformin-only group had an HbA1c 3.27 percentage points lower than the other-HAART-plus-insulin group, with a p value of 0.014.

The authors are careful about how these numbers should be interpreted. They note that the findings align with clinical practice, in which more severe diabetes cases are typically escalated to insulin or to additional oral agents. A patient whose diabetes is aggressive enough to require insulin is, almost by definition, harder to control than one who can be managed with metformin alone, so the observed differences in HbA1c likely reflect underlying disease severity as much as any direct pharmacological effect of the antiretroviral regimens themselves. This is a crucial caveat for a cross-sectional design, which captures a single moment in time and cannot establish whether a particular drug combination caused better or worse glucose control. The researchers explicitly describe their results as baseline descriptive data and call for prospective studies to examine the practice of switching diabetic patients away from dolutegravir.

Beyond glucose, the study examined a panel of metabolic and organ-function markers that are often overlooked in resource-limited settings. Alkaline phosphatase was elevated above 120 units per liter across all six groups, with the highest levels seen in the groups whose treatment included insulin. Gamma-glutamyl transferase elevations in the 40 to 60 units per liter range were observed in the metformin-only group and in the TDF/3TC/EFV-plus-insulin group. Importantly, the transaminases alanine aminotransferase and aspartate aminotransferase, the classic markers of hepatocellular injury, remained within normal ranges across all groups, with mean values of 21.7 plus or minus 12.5 and 20.5 plus or minus 5.8 units per liter respectively. Elevated total cholesterol and triglycerides appeared only in the group taking TDF/3TC/EFV with insulin, a pattern that echoes the known lipid effects of both insulin therapy and some antiretroviral agents.

Kidney function, a persistent concern for patients on tenofovir disoproxil fumarate, appeared well preserved. The estimated glomerular filtration rate, calculated using the contemporary CKD-EPI 2021 formula, averaged 97.5 plus or minus 14.8 milliliters per minute per 1.73 square meters of body surface area, a value consistent with normal renal clearance. That finding is clinically meaningful because TDF has long been associated with proximal tubular injury in some patients, and the combination of HIV, diabetes, and tenofovir could theoretically compound renal risk. In this cohort, at least over the observation window, the kidneys held their ground.

What emerges from Lira is less a verdict on any single drug than a portrait of a treatment landscape in transition. As dolutegravir becomes the default first-line option across the region, clinicians are increasingly making individualized decisions to move patients with diabetes onto older regimens, often without robust evidence about the metabolic trade-offs involved. This study provides the first quantitative baseline for such decisions in a Ugandan regional hospital, showing that HIV control remains excellent across all non-dolutegravir regimens, that glycemic outcomes differ substantially by treatment combination in ways that likely track disease severity, and that liver and kidney function are broadly preserved even as alkaline phosphatase elevations raise questions worth pursuing. The researchers, who declare no competing interests, argue that the next step must be longitudinal work that follows patients before and after a switch away from dolutegravir, so that cause and effect can finally be separated from correlation. For the growing number of people navigating both HIV and diabetes in northern Uganda and beyond, that evidence cannot come soon enough.

Subject of Research: Glycemic control and metabolic parameters in HIV-positive patients with type 2 diabetes on non-dolutegravir antiretroviral regimens in Uganda

Article Title: Glycemic control and metabolic parameters among HIV-positive diabetic patients on non-dolutegravir-based antiretroviral regimens at lira regional referral hospital, uganda: a cross-sectional study

Article References: Wandera, A., Nakaziba, R., Okello, N., Wandera, S. K., Otim, T. C., & Olwa, F. (2026). Glycemic control and metabolic parameters among HIV-positive diabetic patients on non-dolutegravir-based antiretroviral regimens at lira regional referral hospital, uganda: a cross-sectional study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02597-0

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02597-0

Keywords: HIV, type 2 diabetes, antiretroviral therapy, dolutegravir, glycemic control, HbA1c, metformin, efavirenz, Uganda, metabolic parameters, liver function, renal function

The research team, based at Selcuk University’s Faculty of Veterinary Medicine, worked with ten male Akkaraman sheep aged eight to twelve months and weighing between 45 and 55 kilograms. The animals were housed under identical conditions with food and water available ad libitum, and the experimental protocol received approval from the university’s ethics committee. Each sheep received mefepronic acid by intramuscular injection into the gluteal muscles at 10 milligrams per kilogram once daily for three days, matching the dose and duration commonly used off-label in the field. Blood samples were drawn before the first injection and again at 24, 48 and 72 hours, allowing the researchers to track each animal against its own baseline in a repeated-measures, self-controlled design.

The analytical strategy was deliberately broad. Using sheep-specific ELISA kits and an autoanalyzer, the team measured a panel of oxidative stress markers: 8-hydroxy-2-deoxyguanosine, the most widely used biomarker of DNA damage from oxidative stress; malondialdehyde, a cytotoxic and mutagenic end product of lipid peroxidation; and the antioxidant enzymes superoxide dismutase, glutathione peroxidase and catalase. Cardiac injury was assessed through creatine kinase-MB isoenzyme and troponin I, while liver and bile duct status was tracked via alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase and total bilirubin. Kidney function was gauged by blood urea nitrogen and creatinine, and lipid metabolism by cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein. Data were tested for normality with the Shapiro-Wilk test, log-transformed where necessary, and analysed with repeated measures ANOVA and Bonferroni post-hoc comparisons.

Clinically, the drug was uneventful. None of the sheep developed fever, shivering, salivation or any other observable adverse reaction over the three-day monitoring window. Beneath that calm surface, however, the serum chemistry told a more nuanced story. Levels of 8-OHdG rose significantly at 24 hours, climbing from a baseline of roughly 4.86 nanograms per millilitre to 7.37, before drifting back toward starting values by 72 hours. Catalase activity, by contrast, declined significantly by the end of the study, falling from 4.22 to 3.02 nanograms per millilitre. Malondialdehyde, superoxide dismutase and glutathione peroxidase all fluctuated without reaching statistical significance, and the authors note that the isolated 8-OHdG spike, unaccompanied by changes in the other oxidative markers, cannot be directly interpreted as genuine DNA damage.

The cardiac findings followed a similar pattern of transient change without clear pathology. Creatine kinase-MB isoenzyme levels jumped significantly at 24 hours, from 0.62 to 1.01 nanograms per millilitre, then returned to near-baseline values. Troponin I, the more cardiospecific biomarker that has largely displaced CK-MB in clinical practice because of its superior specificity for heart muscle, showed no significant change at any time point. The authors place this result in context by explaining that CK-MB is a sensitive but nonspecific marker: it is produced predominantly in cardiac muscle but also in small amounts in the uterus, small intestine, diaphragm, tongue and prostate, and its rapid clearance from circulating blood has historically limited its diagnostic value. Given that troponin I remained stable, the team concluded that no clinically significant myocardial damage occurred during the short observation period.

Kidney and lipid parameters produced the study’s most intriguing metabolic signals. Blood urea nitrogen fell significantly by 72 hours, from 11.31 to 9.01 milligrams per decilitre, though the decline stayed within published reference ranges for sheep and serum creatinine, the more reliable indicator of glomerular filtration rate, remained unchanged throughout. High-density lipoprotein dropped significantly by 72 hours and low-density lipoprotein fell significantly at both 24 and 72 hours, the latter sliding from 27.50 to 19.00 milligrams per decilitre. Cholesterol and triglycerides also trended downward without reaching significance. The authors suggest these lipid shifts are consistent with the drug’s known metabolic activity and may even underpin its reported benefits in fatty liver syndrome, where reducing circulating lipid load could ease the burden on an already compromised liver.

Liver markers were similarly unremarkable. Alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase and total bilirubin all showed nonsignificant decreases over the study period, a direction of change that fits comfortably with the drug’s intended choleretic action rather than suggesting hepatocellular injury. This aligns with earlier reports in other species: mefepronic acid given to dairy cows before and after calving had no adverse effect on serum lipid parameters and appeared to improve postpartum liver function, and the compound has been used as supportive therapy in dogs with hepatopathy. Rat studies have also reported a limited protective effect against hepatic steatosis, and off-label use in sheep has been credited with helping correct the severe metabolic liver dysfunction associated with liver fluke infection when combined with triclabendazole and levamisole.

The study’s design choices carry both strengths and constraints that shape how the results should be read. The self-controlled, repeated-measures framework meant each animal served as its own reference, which the authors argue reduced the noise introduced by inter-individual biological variation and allowed clean tracking of time-dependent changes after dosing. But the absence of a separate control group means drug-related effects cannot be fully disentangled from spontaneous or time-dependent physiological drift. The sample of ten healthy male sheep, monitored for only 72 hours, further limits generalisation. The authors are explicit that these are preliminary data, and they flag particular caution for animals with pre-existing heart disease or other risk factors, where the transient CK-MB elevation and catalase decline could behave differently.

Species-specific idiosyncrasies in drug safety provide a compelling rationale for the work. Tilmicosin, a macrolide antibiotic considered safe in cattle, has been reported to cause mortality in goats. Ivermectin, a mainstay antiparasitic that is generally well tolerated in dogs, produces toxicity and death in Collies carrying the MDR1 mutation. Against that backdrop, assuming that a drug proven safe in five target species will behave identically in a sixth is clearly untenable. The oxidative stress angle added further urgency: prior work in dairy cattle suggested mefepronic acid can reduce lipid peroxidation in hepatocytes, and researchers have proposed that the drug, alone or with ammonium molybdate, might help in copper poisoning cases in sheep, making it important to know whether the compound itself provokes oxidative damage at therapeutic doses.

The overall verdict is one of conditional reassurance. In healthy sheep at the standard 10 milligrams per kilogram intramuscular dose for three days, mefepronic acid caused no clinical adverse effects, no clinically significant disturbance of liver or kidney function, and no evidence of myocardial injury by the most specific available biomarker. The transient 8-OHdG rise, catalase fall and CK-MB bump are best interpreted as subclinical, self-resolving fluctuations rather than signs of organ damage, though the authors caution that such effects could prove more pronounced in sick, pregnant or otherwise compromised animals. They call for future studies in different breeds and in diseased or pregnant sheep to establish whether the drug’s growing off-label repertoire in ovine medicine, from fertility support to metabolic disease, can rest on firmer safety ground. For now, the message to practitioners is measured: the drug appears tolerable in healthy ewes and rams, but risk groups deserve closer monitoring.

Subject of Research: Safety and biochemical effects of extra-label mefepronic acid administration in sheep

Article Title: Safety Assessment of Mefepronic Acid in Sheep

Article References: Canbar, R., Parlak, T. M., Uslu, M., & Yazar, E. (2026). Safety Assessment of Mefepronic Acid in Sheep. Veterinary Medicine and Science, 12(5), Article e71236. https://doi.org/10.1002/vms3.71236

Image Credits: AI Generated

DOI: 10.1002/vms3.71236

Keywords: mefepronic acid, sheep, veterinary pharmacology, oxidative stress, choleretic, cardiac biomarkers, CK-MB, troponin I, liver function, kidney function, lipid metabolism, drug safety

The retracted review concerned a class of pollutants with genuine toxicological importance. Polycyclic aromatic hydrocarbons, often abbreviated PAHs, are a large family of organic compounds composed of fused aromatic rings. They form whenever organic material is incompletely burned, which means that the dominant human exposure routes include tobacco smoke, charred and grilled food, wood and coal combustion, vehicle exhaust, and a wide range of occupational settings such as asphalt paving, coking, and aluminum smelting. Because many PAHs are lipophilic and are metabolized in the liver, the organ is both the principal site of their biotransformation and a plausible target for their toxic effects. Enzymes of the cytochrome P450 family convert parent PAHs into reactive metabolites, some of which form DNA adducts and protein adducts, generate oxidative stress, and can disturb hepatocellular function. Serum markers such as alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase are therefore commonly used in environmental epidemiology as indirect indicators of liver injury in populations exposed to air pollution.

Against that background, a systematic review of observational studies examining PAH exposure and liver function would have been a useful contribution, since observational evidence in this field is scattered across occupational cohorts, general-population surveys, and studies using biomarkers of internal dose such as urinary hydroxylated PAH metabolites. The retraction does not establish that the underlying hypothesis is wrong; rather, it removes this particular synthesis from the citable literature because the journal can no longer vouch for its integrity. That distinction matters for readers who encounter the paper through search engines or reference managers: the retraction notice is now attached to the article record, and the canonical digital object identifier for the notice itself is 10.1007/s11869-026-02101-6, while the original article was published under a different identifier in 2023.

The first ground for retraction, substantial overlap with a previously published article, points to one of the most closely watched problems in contemporary scholarly publishing. Textual and data overlap between papers can range from redundant publication, in which the same work is submitted to multiple journals, to outright plagiarism, in which text or findings are reused without attribution. In this case, the journal identified the overlapping publication as a paper that itself has since been retracted: a systematic review on the association between prenatal exposure to polycyclic aromatic hydrocarbons and childhood intelligence, published in Environmental Science and Pollution Research in 2023, which the notice explicitly labels as a retracted article. Two authors were common to both papers. The fact that the companion article was also retracted suggests a broader pattern in which a cluster of related manuscripts, produced by large and geographically dispersed author teams, came under editorial scrutiny at more than one journal.

The second ground, that multiple references appeared to be irrelevant, is a hallmark that research-integrity specialists associate with certain forms of coordinated manuscript production. Citation manipulation, whether intended to inflate the metrics of particular journals or authors, or simply the byproduct of template-driven writing, undermines the scholarly function of a reference list, which is supposed to document the evidentiary basis of a review’s claims. In a systematic review, where the entire contribution depends on the transparent identification, screening, and synthesis of primary studies, irrelevant citations are not a cosmetic flaw. They make it impossible for readers to verify which studies were actually considered, how inclusion and exclusion criteria were applied, and whether the pooled conclusions follow from the evidence. When such problems surface and authors decline to engage with the journal, editors are left with little alternative to retraction.

The authorship pattern of the retracted paper is itself noteworthy. The article listed authors affiliated with institutions in Indonesia, Saudi Arabia, Russia, Iraq, India, Colombia, Poland, Yemen, Uzbekistan, and Iran, a span of countries that would be unusual for a review of environmental health data focused on any single population. Large, internationally scattered author lists with limited apparent connection to the study subject have become a recognized red flag in the wave of retractions that has swept through the scientific literature in recent years, particularly among papers produced by commercial paper mills. Publication ethics watchdogs and major publishers have documented tens of thousands of retractions in recent years, a substantial fraction of them linked to systematic manipulation of the publishing pipeline rather than to honest error. While the retraction notice in this case does not allege paper-mill involvement, the combination of overlapping text, irrelevant references, and non-response from a dozen or more authors fits a familiar profile.

The non-response of the authors is a significant procedural element. Journals typically follow a due-process protocol when integrity concerns arise: they contact the corresponding authors, describe the concerns, and invite an explanation or rebuttal, sometimes allowing weeks or months for a reply. When authors engage, the outcome may be a correction, an expression of concern, or, if the explanation is unsatisfactory, retraction. When authors do not respond at all, editors must weigh the harm of leaving a flawed paper in the literature against the fairness of acting without the authors’ side of the story. In this instance the Editor-in-Chief concluded that the evidence of overlap and citation problems, combined with the authors’ silence, justified withdrawal of the article and a public statement that confidence in the work could no longer be maintained. The notice also records that none of the authors responded to the publisher’s correspondence about the retraction itself.

For the environmental health community, the retraction carries practical consequences. Systematic reviews are frequently cited in risk assessments, in the design of subsequent studies, and in policy documents that summarize the state of the evidence on pollutant-health associations. A retracted review on PAHs and liver function cannot be used as a summary of that evidence, and researchers citing the field should rely on the primary observational studies and on reviews that have survived editorial scrutiny. At the same time, the underlying scientific question remains open and legitimate. Epidemiologists continue to investigate whether chronic low-level PAH exposure, as measured by urinary metabolites or by proxies such as traffic-related air pollution, is associated with altered liver enzymes, non-alcoholic fatty liver disease, or other hepatic outcomes. Well-conducted reviews that document their search strategies, register their protocols, and report their screening decisions transparently remain the right tool for answering that question.

The episode also illustrates the machinery of post-publication correction that major publishers now deploy. The retraction notice is linked to the article record through the CrossMark service, which allows readers checking a document to verify whether they are viewing the current, authoritative version. The notice identifies the journal, the volume and article number, the publication date, and the relationship to the original paper, and it cites the retracted companion article explicitly so that readers can trace the overlap. This apparatus does not erase the flawed paper from databases, since retracted articles remain online with their notices attached; that permanence is deliberate, preserving the scholarly record while warning readers away from relying on the content. It also creates a public trail that institutions can consult when evaluating the output of researchers involved in retractions.

Ultimately, the case is a reminder that the credibility of environmental health science depends as much on the integrity of synthesis as on the quality of the underlying measurements. Air pollution research has produced some of the most consequential public health findings of the past decades, linking fine particulate matter, nitrogen dioxide, and combustion byproducts to cardiovascular, respiratory, and metabolic disease, and PAHs remain a plausible contributor to hepatic toxicity given their metabolism in the liver and their capacity to form reactive adducts. But every meta-analytic claim inherits the weaknesses of the papers it aggregates, and a review built on irrelevant citations and duplicated material cannot support confident conclusions. The retraction of this systematic review removes a compromised summary from the literature, flags a cluster of related concerns across at least two journals, and underscores the growing vigilance of editors and integrity researchers toward the patterns of overlap, citation manipulation, and authorial silence that have come to define the current era of scholarly self-correction.

Subject of Research: Retraction of a systematic review on polycyclic aromatic hydrocarbon exposure and liver function due to article overlap and citation integrity concerns

Article Title: Retraction Note: Exposure to polycyclic aromatic hydrocarbons and liver function: a systematic review of observational studies

Article References: Efriza, E., Alshahrani, S. H., Zekiy, A. O., Lateef Al‑Awsi, G. R., Sharma, S. K., Ramírez‑Coronel, A. A., Shakeel, N., Riadi, Y., Aminov, Z., Zabibah, R. S., Mustafa, Y. F., & Najafi, M. L. (2026). Retraction Note: Exposure to polycyclic aromatic hydrocarbons and liver function: a systematic review of observational studies. Air Quality, Atmosphere & Health, 19(10), Article 214. https://doi.org/10.1007/s11869-026-02101-6

Image Credits: AI Generated

DOI: 10.1007/s11869-026-02101-6

Keywords: retraction, polycyclic aromatic hydrocarbons, liver function, systematic review, research integrity, Air Quality Atmosphere & Health, citation manipulation, environmental health, hepatotoxicity, air pollution, Springer Nature, publishing ethics

The research, led by a team at Beijing Children’s Hospital of Capital Medical University, analyzed data from 257 pediatric patients treated with sirolimus, drawing on a remarkable 766 to 892 blood samples collected during routine care. Rather than treating adverse reactions as isolated events, the investigators systematically quantified the relationship between steady-state trough concentrations of sirolimus, known as Cmin, and three of the drug’s most clinically significant toxicities: myelosuppression, abnormal liver function, and dyslipidemia. Trough concentrations, measured immediately before the next dose, are the standard metric for therapeutic drug monitoring of sirolimus, because the drug’s effects and toxicities track closely with whole-blood levels.

What makes the study methodologically distinctive is its pairing of two computational approaches that rarely meet in pharmacology. The first is Bayesian kernel machine regression, or BKMR, a flexible statistical framework originally developed to assess the health effects of complex environmental exposures such as air pollutant mixtures. BKMR excels at modeling nonlinear relationships and interactions among multiple simultaneous exposures without imposing rigid functional forms, which makes it well suited to the messy reality of pediatric drug monitoring, where age, weight, disease type, concomitant medications, and treatment duration all shift the toxicity landscape. The second component is a population pharmacokinetic model, or PopPK, which describes how sirolimus is absorbed, distributed, and cleared across a heterogeneous population of children and predicts individual exposure from dosing history and patient characteristics.

By integrating the two into a unified BKMR-PopPK framework, the researchers created something more powerful than either method alone. The PopPK model translates a proposed dose into a predicted trough concentration for a specific child, while the BKMR layer converts that predicted exposure into a quantified risk of myelosuppression, liver injury, or dyslipidemia. The result is a tool for model-informed precision dosing, an approach that replaces one-size-fits-all weight-based dosing with individualized regimens designed to keep each patient inside a safety window that is narrow enough to prevent toxicity but wide enough to control the underlying vascular lesion.

The analysis identified disease complexity and duration of therapy as key modifiers of risk. Children with complex or mixed vascular malformations faced different exposure-response relationships than those with simpler, more localized lesions, and the risks of certain toxicities grew as treatment extended over months. Based on these quantitative relationships, the team recommends routine trough concentration monitoring within two distinct safety windows: 5.0 to 7.5 nanograms per milliliter for children with simple lesions or milder disease, and 8.0 to 10.2 nanograms per milliliter for those with complex or mixed vascular malformations, who may require higher exposure to achieve disease control.

The temporal dimension of the findings carries particular weight for families and clinicians committed to long-term therapy. Sirolimus treatment for vascular anomalies often continues for a year or more, and the study’s results indicate that vigilance must intensify rather than relax as months accumulate. Beyond six months of treatment, the authors call for heightened surveillance for myelosuppression and dyslipidemia through regular screening of blood counts and lipid panels. This is a meaningful departure from practice patterns in which monitoring may become less rigorous once a patient has tolerated the drug through the early treatment period.

Each of the three adverse reactions examined carries its own clinical stakes. Myelosuppression, the suppression of bone marrow activity, can lower blood cell counts and increase vulnerability to infection, anemia, and bleeding. Abnormal liver function signals hepatotoxicity that, if unchecked, can progress to more serious injury. Dyslipidemia, the elevation of blood lipids, is subtler but consequential in children, because lipid abnormalities established early in life can seed long-term cardiovascular risk. By quantifying how each toxicity relates to trough concentration, the framework allows clinicians to weigh these distinct risks against the therapeutic benefit of suppressing the malformation itself.

The broader significance of the work extends beyond vascular anomalies. Rare pediatric diseases pose a persistent methodological dilemma: patient populations are small, clinical trials are difficult to mount, and safety data are often fragmentary or anecdotal. The authors argue that their integrated framework offers a template for extracting rigorous, quantitative safety insights from the routine clinical data that even small cohorts generate. In doing so, the study addresses a genuine knowledge gap. Prior research had suggested a strong link between sirolimus exposure and adverse reactions, but the quantitative relationship, the actual probabilities of toxicity at given concentrations, had remained undefined, leaving clinicians to rely on empirical dosing inherited from transplant medicine.

Therapeutic drug monitoring itself is not new to sirolimus; the drug’s narrow therapeutic index has long demanded blood level measurement. What is new is the precision with which those measurements can now be interpreted. Instead of a single broad target range applied to every child, the study supports disease-specific and time-dependent target ranges, embedded within a predictive model that can forecast an individual patient’s exposure and toxicity risk before a dose is even administered. The retrospective design, approved by the Institutional Ethics Committee of Beijing Children’s Hospital, means the findings will need prospective validation, but the sample size and the density of pharmacokinetic sampling lend the conclusions substantial credibility.

For the children who depend on sirolimus to shrink lesions that compress airways, deform faces, or bleed unpredictably, the study promises something deceptively simple: a better chance of staying on the drug long enough for it to work. Treatment discontinuation driven by adverse reactions is one of the most common reasons vascular anomaly therapy fails, and every avoidable discontinuation represents a child whose disease resumes its advance. By converting pharmacological data into individualized risk estimates and dosing guidance, the BKMR-PopPK framework moves pediatric vascular anomaly care a decisive step closer to the era of precision medicine, where the question is no longer simply how much drug to give, but how much drug this particular child can safely carry.

Subject of Research: Quantifying sirolimus exposure-response safety relationships in pediatric vascular anomalies using an integrated BKMR-PopPK framework

Article Title: Safety of sirolimus in pediatric vascular anomalies: a BKMR-PopPK exposure–response framework for individualized risk and dosing

Article References: Liu, B., Xu, X.-L., Wang, J.-L., Li, J., Wu, Y.-X., Zhang, X.-X., Liu, Q.-Y., Zhao, Y.-M., Guo, P., Zhang, R.-Q., Zhou, H., Mao, X.-T., Jia, Y.-M., Cheng, X.-L., Wang, S.-C., & Wang, X.-L. (2026). Safety of sirolimus in pediatric vascular anomalies: a BKMR-PopPK exposure–response framework for individualized risk and dosing. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01076-9

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01076-9

Keywords: sirolimus, vascular anomalies, pediatrics, adverse drug reactions, therapeutic drug monitoring, population pharmacokinetics, Bayesian kernel machine regression, precision dosing, myelosuppression, dyslipidemia, liver function, rare diseases

The research, led by Lubin Gou and Junqiang Lei of the First Hospital of Lanzhou University and Lanzhou University’s First Clinical Medical College, focused on patients with liver cirrhosis without overt hepatic encephalopathy, a stage abbreviated LC-nOHE. This is the window in which the disease has already compromised liver function but has not yet produced the confusion, disorientation, and personality changes that define overt hepatic encephalopathy. Understanding what happens in the brain during this silent phase is critical, because it may reveal the earliest opportunities for intervention before irreversible damage takes hold.

The team recruited 86 patients with liver cirrhosis but no overt encephalopathy, along with 62 healthy controls, and acquired high-resolution three-dimensional T1-weighted magnetic resonance images of every participant’s brain. From these scans, the researchers extracted the volume of the thalamus and three distinct measures of cortical shape: cortical thickness, sulcal depth, and fractal dimension, a measure of the complexity of the brain’s folded surface. Rather than examining these features in isolation, the investigators constructed structural covariance networks, mathematical maps in which brain regions are connected if their anatomical features covary across individuals. Such networks are widely used as proxies for coordinated maturational and degenerative processes, offering a window into how brain regions change together as a system.

The results were striking at multiple levels. Compared with healthy controls, patients with cirrhosis showed enlargement of the thalamus alongside a broad range of cortical morphological abnormalities. At the level of whole-network organization, the thalamo-cortical structural covariance networks of patients displayed reduced segregation, meaning the brain’s specialized modules were less clearly differentiated, and decreased integration, meaning efficient communication across the network was impaired. These two properties, segregation and integration, are hallmarks of a healthy, well-organized brain, and their simultaneous deterioration suggests a fundamental disruption of the architecture that supports cognition.

Zooming in on individual network nodes, the researchers found that the centrality of three regions was significantly reduced in patients: the thalamus itself, the supramarginal gyrus, and the insula. Each of these regions plays a recognizable role in the syndrome. The thalamus relays sensory and motor signals to the cortex and regulates consciousness and alertness; the supramarginal gyrus contributes to language and spatial cognition; and the insula supports interoception and awareness of the body’s internal state. Reduced centrality in these hubs indicates that they had lost influence within the network, becoming less connected to the rest of the brain’s structural architecture.

Perhaps the most clinically significant finding was the relationship between brain changes and liver function. The degree centrality of the thalamus was negatively correlated with liver function measures, meaning that the worse the liver was performing, the more the thalamus had lost its position within the brain’s structural network. This correlation ties the brain imaging directly to the severity of liver disease and supports the idea that the thalamus sits at the front line of the liver-brain axis, the pathway by which hepatic dysfunction, circulating toxins such as ammonia, and systemic inflammation are translated into neural injury.

To move beyond correlation and probe causality, the team applied a technique called causal analysis of structural covariance networks, or CaSCN. This approach examines how changes in one brain region’s morphology relate to changes in others across the progression of disease, allowing researchers to ask which region leads and which follows. The analyses demonstrated that thalamus volume had causal effects on the alterations of cortical morphology as liver dysfunction progressed. In other words, the data are consistent with a model in which the thalamus is not merely another victim of cirrhosis but an active driver, propagating structural changes outward to the cortical regions with which it is connected.

The study then took an unusual additional step: linking the brain imaging to genomics through imaging transcriptomics. Using normative gene-expression profiles from the Allen Human Brain Atlas, the researchers evaluated whether the spatial pattern of causal effects across the cortex overlapped with the spatial distribution of specific genes. It did. The pattern of causal path coefficients was spatially correlated with the expression of particular genes in the normative atlas, suggesting that the cortical regions most vulnerable to thalamus-driven change are also those with distinctive molecular signatures. Gene ontology analyses pointed toward enrichment in biological processes, molecular functions, and cellular components that may help explain why some cortical areas are preferentially affected while others are relatively spared.

Taken together, the findings provide a comprehensive, multilevel view of how the thalamo-cortical circuit becomes progressively vulnerable in liver cirrhosis before overt encephalopathy appears. The enlargement of the thalamus, consistent with processes such as edema or glial changes reported in prior literature on hepatic encephalopathy, appears to initiate a cascade that erodes the segregation and integration of the entire structural network, strips key hubs of their centrality, and reshapes the cortex in patterns governed partly by underlying gene expression. Because the thalamus’s network position tracks liver function, measures of thalamo-cortical network integrity could potentially serve as imaging biomarkers for identifying patients at risk of progressing to overt hepatic encephalopathy, enabling earlier monitoring and treatment.

The authors emphasize that these findings offer a potential mechanism-driven framework for understanding the earliest brain consequences of liver disease, one that connects organ function, network neuroscience, and transcriptomics within a single analytical pipeline. The work was supported by the Lanzhou University First Affiliated Hospital Foundation and the Science and Technology Department of Gansu Province, and it was approved by the Institutional Ethics Committee of the First Hospital of Lanzhou University. As cirrhosis continues to affect millions worldwide, studies like this one bring clinicians closer to detecting, and perhaps preventing, the neurological toll of liver disease before it announces itself in the clinic.

Subject of Research: Structural covariance network alterations of the thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy

Article Title: Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics

Article References: Gou, L., Ren, H., Xu, W., Gao, Y., Wang, S., Zhang, Y., Dou, Y., & Lei, J. (2026). Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02790-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02790-6

Keywords: liver cirrhosis, hepatic encephalopathy, thalamus, thalamo-cortical circuit, structural covariance network, MRI, liver-brain axis, imaging transcriptomics, cortical thickness, liver function, neuroimaging, Allen Human Brain Atlas